CONNECT WITH US
HealthTech

HealthTech

ACAAI: Considerable delay seen from Rx to approval for children's biologics

Medical Xpress logo

Published on

Add as a preferred source on Google
ACAAI: Considerable delay seen from Rx to approval for children's biologics

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.

Mark Holland, M.D., from the Children's Mercy Hospital in Kansas City, Missouri, and colleagues examined the landscape of PA denials of biologic therapies by payers in a retrospective chart review of pediatric patients (median age, 11.4 years; 50.3% male and 49.7% female) who had been prescribed biologics by allergists for atopic conditions. The analysis included omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab, which were prescribed between 2018 and 2026.

The researchers identified 326 prescriptions for biologic therapy. The most frequently prescribed biologic was omalizumab, which accounted for more than half of the biologics prescribed (55.8%), followed by dupilumab (26%). Overall, 39.3% of the prescriptions requiring a PA were denied. Not meeting insurance criteria and a trial of a prerequisite were the most common reasons for denial (24.4% and 23.4%, respectively). There was a mean of 32.65 days from prescription of medication to approval.

, also from the Children's Mercy Hospital, said in a statement.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.